|
Basic Characteristics of Mutations
|
|
Mutation Site
|
V207I |
|
Mutation Site Sentence
|
Specifically, the following mutations were found: rtL180M, rtM204V, rtV207M/L/I, rtS213T, rtA181T, rtV214A, rtQ215S, rtN236T, rtP237H, rtN238T, rtT184L, and rtM250L. In these mutations, the drug-resistant HBV mutants related to other NUCs such as lamivudine (LAM) and entecavir (ETV) were also found though patients didn’t receive LAM or ETV treatment |
|
Mutation Level
|
Amino acid level |
|
Mutation Type
|
Nonsynonymous substitution |
|
Gene/Protein/Region
|
RT |
|
Standardized Encoding Gene
|
P
|
|
Genotype/Subtype
|
- |
|
Viral Reference
|
-
|
|
Functional Impact and Mechanisms
|
|
Disease
|
Hepatitis B Virus Infection
|
|
Immune
|
- |
|
Target Gene
|
-
|
|
Clinical and Epidemiological Correlations
|
|
Clinical Information
|
Y |
|
Treatment
|
- |
|
Location
|
China |
|
Literature Information
|
|
PMID
|
25493022
|
|
Title
|
Resistant mutants induced by adefovir dipivoxil in hepatitis B virus isolates
|
|
Author
|
Jiang SW,Yao LP,Hu AR,Hu YR,Chen SX,Xiong T,Gao GS,Liang XY,Ding SX,Weng PJ
|
|
Journal
|
World journal of gastroenterology
|
|
Journal Info
|
2014 Dec 7;20(45):17100-6
|
|
Abstract
|
AIM: To investigate the loci of adefovir dipivoxil (ADV)-induced resistance in hepatitis B virus (HBV) isolates and optimize the management of ADV-treated patients. METHODS: Between June 2008 and August 2010, a cross-sectional control study was conducted comprising 79 patients with chronic HBV infection-related liver disease who had been administered ADV monotherapy. Patients underwent liver imaging. Serum DNA extracts were analyzed for HBV DNA levels, genotypes, and serology markers, and deep sequencing of the HBV P gene was performed. RESULTS: ADV-resistant patients were found either with a single mutated locus, or with coexisting mutated loci. The most prevalent mutations were rtA181T, rtV214A, and rtN236T. Twenty-six patients had more than two mutated loci. The mutants were distributed among the patients without any significant affinity for gender, age, end-stage of liver disease, complications of non-alcoholic fatty liver disease, or HBV DNA levels. Patients with the rtA181T mutant were primarily infected with genotype C and e-antigen negative HBV, while patients with the rtN236T mutant were primarily infected by genotype B HBV (chi(2) = 6.004, 7.159; P = 0.023, 0.007). The duration of treatment with ADV was shorter in the single mutant group compared with the multi-mutant group (t = 2.426, P = 0.018). CONCLUSION: Drug-resistant HBV mutants are complex and diverse. Patients should receive the standard and first-line antiviral treatment, strictly comply with medication dosage, and avoid short-term withdrawal.
|
|
Sequence Data
|
-
|
|
|